Qing Pan

Title: Qing Pan: Innovator in Corneal Allograft Rejection Prevention

Introduction

Qing Pan is a notable inventor based in Hangzhou, China. She has made significant contributions to the field of biomedical engineering, particularly in the area of corneal transplantation. Her innovative work focuses on developing advanced solutions to prevent corneal allograft rejection.

Latest Patents

Qing Pan holds a patent for "Glucocorticoid-loaded nanoparticles for prevention of corneal allograft rejection and neovascularization." This invention involves particles that encapsulate a glucocorticoid, such as dexamethasone sodium phosphate (DSP), within a biodegradable matrix like poly(lactic-co-glycolic acid) (PLGA). These nanoparticles are densely coated with hydrophilic polymers, such as PEG or PLURONIC® F127, allowing for the sustained release of DSP for up to seven days in vitro. This technology has the potential to significantly improve outcomes in corneal graft procedures by preventing rejection and neovascularization.

Career Highlights

Qing Pan is affiliated with Johns Hopkins University, where she continues her research and development efforts. Her work has garnered attention for its innovative approach to addressing critical challenges in corneal transplantation.

Collaborations

Qing Pan collaborates with esteemed colleagues, including Qingguo Xu and Walter J. Stark. These partnerships enhance her research capabilities and contribute to the advancement of her projects.

Conclusion

Qing Pan's contributions to the field of corneal transplantation through her innovative patent demonstrate her commitment to improving medical outcomes. Her work exemplifies the impact of research and innovation in addressing significant health challenges.